Dec. 17, 2014, 7:32 AM
Dec. 16, 2014, 7:42 AM
- CVS Health (NYSE:CVS) approves a new $10B share buyback program on top of a quarterly dividend boost to $0.35/share.
- The company sees FY15 EPS of $5.05-$5.19 vs. $5.11 consensus.
- Free cash flow of $5.9B to $6.2B is expected to be generated next year.
- CVS +0.2% premarket.
Dec. 11, 2014, 9:30 AM
- Retail sales struck their biggest gain since March on broad strength.
- What's working: Strong growth was seen in auto parts (PBY, ORLY, AZO, AAP, MNRO) with the broad parts category showing year-over-year sale growth of over 8% in November. Sales were up 6.8% Y/Y for health and personal care stores (ULTA, SBH, CVS, WAG, RAD) during the month.
- What's not working: Department stores (DDS, M, SSI, BONT, SHLD, JCP, KSS, JWN) went backwards with sales off 1.1% from a year ago. No surprise, but sales at gas stations (CASY, KR, PTRY) also fell off from a year ago.
- Retail ETFs: XLY, XRT, VCR, RTH, RETL, IYK, FXD, IYC, FDIS, SCC, UCC, PMR, UGE, RCD, SZK.
Nov. 25, 2014, 8:18 AM
- Pharmacy benefits manager Express Scripts (NASDAQ:ESRX) is at the forefront of an increasing wave of resistance to the high prices of new drugs from pharma and biotech firms, some which cost as much as $50K per month. Pharmaceutical spending in the U.S. is $270B and may breach $500B in five years. ESRX's method of controlling costs is to refuse to pay for them. For 2015, for example, it is excluding 66 branded drugs from its main formulary, an increase of 18 from 2014's 48. On the list is Johnson & Johnson's (NYSE:JNJ) rheumatoid arthritis drug Simponi (golimumab) which costs $3K per month.
- Other prescription benefits managers are employing similar tactics. CVS Health (NYSE:CVS) will exclude 95 drugs from its 2015 formulary including Pfizer's (NYSE:PFE) multiple sclerosis med Rebif (interferon beta-1a) which costs $5K for a four-week supply.
- Governments are pushing back as well. Among 42 state Medicaid programs, 27 pay for Gilead Sciences' HCV med Sovaldi (sofosbuvir) only for patients with severe liver damage while others impose coverage limitations for patients with recent substance-abuse problems. In the U.S., the full regimen cost is $84K. Recently, Britain's National Institute for Health and Care Excellence (NICE) balked at recommending reimbursement for Roche's (OTCQX:RHHBY) blood cancer drug Gazyvaro (obinutuzumab).
- Ninety percent of commercial health plans require pre-approval of specialty drugs, up from 82% in 2011.
- Previously: Roche's Gazyvaro not NICE in the UK
- Previously: Global drug tab will breach trillion dollar mark this year
- ETFs: IBB, BIB, IRY, BIS, IXJ, DRGS
- Related tickers: (NYSE:NVS) (NYSE:AZN) (NASDAQ:AMGN) (NASDAQ:BIIB) (NASDAQ:CELG) (NYSE:LLY) (NYSE:SNY) (NYSE:ABT) (NYSE:ABBV) (NYSE:BMY) (NYSE:MRK) (NYSE:GSK)
Nov. 4, 2014, 8:08 AM
- CVS Health (NYSE:CVS) Q3 results ($M): Revenues: 35,021 (+10%); Gross Profit: 6,468 (+7%); Operating Income: 2,246 (+4%); Net Income: 948 (-24%); EPS: 0.81 (-21%); Quick Assets: 1,210 (-71%); CF Ops (9 mo.): 4,714 (+11%).
- 2014 Guidance: non-GAAP EPS: $4.47 - 4.50 from $4.43 - 4.51; GAAP EPS from continuing operations: $3.93 - 3.96; CF Ops: $7.4B - 7.7B from $7.2B - 7.5B, Free Cash Flow $5.7B - 6.0B from $5.5B - 5.8B.
- Q4 Guidance: non-GAAP EPS: $1.18 - 1.21; GAAP EPS from continuing ops: $1.12 - 1.15.
- Shares up 1% premarket on light volume.
Nov. 4, 2014, 7:05 AM
Nov. 3, 2014, 5:30 PM
- AER, AFSI, AKS, ALLT, ARCC, ARCO, ARRY, ATRO, AYR, BABA, BDX, BKW, BLMN, CCG, CIE, CLDT, CONE, CVS, DISCA, DISH, DWRE, DX, EL, EMR, ENBL, EOG, ETR, EXH, EXLP, EXPD, FE, GDP, GLT, HCLP, HCN, HCP, HEP, HMSY, HPT, HSNI, HW, ICE, IFF, IMN, IP, IPXL, IRC, IRWD, KORS, LINC, LINE, LNCE, MFA, MSI, MWW, NCT, NGLS, NNN, NTI, NWN, ODP, OZM, PCLN, PPL, RBA, REGN, RESI, RGS, RHP, RIGL, RRGB, SC, SGNT, SRE, TESO, TGH, TICC, TIME, TLM, TRP, VLO, VMC, VSI, WLK, WNR, WRES, ZBRA, ZTS
Oct. 29, 2014, 1:42 PM
- Walgreen (WAG -1.2%) has taken to social media to tell iPhone 6 and 6 Plus owners that Apple Pay is accepted at all of the drugstore chain's stores.
- Rivals Rite Aid (RAD +3.7%) and CVS Caremark (CVS -0.2%) don't accept payments through the Apple app as they wait for a competing mobile payments system called CurrentC to be introduced next year.
Oct. 28, 2014, 11:32 AM
- Redbook notes the timing of Halloween on a Friday is giving a boost to merchandise sales related to the holiday as more consumers prep for parties and celebrations.
- Both Redbook and ICSC's weekly read on retail store sales showed year-over-year improvement with Halloween sales a factor.
- Stores have also been extending their hours to draw in more shoppers.
- Looking for a Halloween boost: DLTR, DG, FDO, KR, SVU, SWY, WMT, TGT, HSY, KRFT, CVS, RAD, WAG, MDLZ.
Oct. 27, 2014, 4:59 AM
- Rite Aid (NYSE:RAD) and CVS (NYSE:CVS) have disabled Apple's (NASDAQ:AAPL) mobile wallet system, Apple Pay, from working in their outlets across the U.S.
- The reason wasn't immediately clear, the NYT reports, although it might have something to do with the drug retailers being part of MCX, a consortium of merchants that is developing an unfinished rival product called CurrentC.
- A major question is whether other MCX retailers, which include Best Buy (NYSE:BBY), Gap (NYSE:GPS) and Walmart (NYSE:WMT), will also cut Apple, and/or whether consumers would revolt at such a move.
- Apple has been working with MasterCard (NYSE:MA) on its system.
Oct. 20, 2014, 10:47 AM
- CVS Health (CVS +1%) plans to charge some customers a $15 co-payment fee for any prescriptions filled at a pharmacy which also sells tobacco products.
- The initiative could boost sales at CVS drugstores as consumers switch to the cheaper option, according to industry insiders.
- Large drugstore chains such as Walgreen (WAG +0.1%) and Rite Aid (RAD +0.6%), along with small independent pharmacies, are expected to cry foul over the CVS strategy.
Oct. 14, 2014, 3:31 PM
- Global growth, foreign-exchange, oil, and small caps are the subject of every client inquiry, says David Kostin. His team's recommendation: Buy "American exceptionalism."
- In Kostin's view, U.S. economy and corporate fundamentals are still strong, with economic growth expected by Goldman economists to be 3.2% next year, the fastest expansion since 2005. Europe is expected to grow just 1%.
- What his team likes are those stocks of companies which have a high proportion of domestic sales, plus sectors like Consumer Staples (XLP -0.1%) and Discretionary (XLY +0.7%) which stand to benefit from lower oil prices (plunging again today).
- As for small caps (IWM +0.9%), Kostin is wary, noting downward earnings revisions have boosted small cap P/E ratios even as prices have declined.
- The list of S&P 500 names capturing two or more of Kostin's themes: GT, GM, PCLN, AMZN, CMCSA, LOW, DG, TSN, ADM, CVS, AVP, WAG, PXD, HAL, JPM, BAC, SCHW, PNC, MS, C, GNW, LNC, MET, THC, AET, UNH, ESRX, HUM, WLP, BIIB, GILD, DAL, CMI, FLR, CRM, JBL, MA, FB, MU, FSLR, VMC, MON, T.
Sep. 24, 2014, 1:50 PM
Sep. 18, 2014, 9:30 AM| 1 Comment
Sep. 12, 2014, 2:02 PM
- Wal-Mart (WMT -0.5%) plans to rebrand all of its Express stores to Neighborhood Market in a move that signals a stronger push into grocery.
- The new strategy means that Neighborhood Market stores will range in size from 15K to 40K square feet.
- The company is still testing the smaller Walmart To Go and Walmart On Campus concepts.
- What to watch: Though there's plenty of retail chains which could be impacted by Wal-Mart's NM push, Gilford Securities reasons that dollar stores (FDO, DLTR, DG) and drugstores (RAD, CVS, WAG) top the list.
Sep. 3, 2014, 2:06 AM
- Coinciding with the sale of its last tobacco product today, CVS Caremark (NYSE:CVS) is unveiling its new corporate name: CVS Health.
- CVS said in February that it would rid all of its 7,700 stores of tobacco products by Oct. 1, but in the end decided to eliminate them one month ahead of schedule.
- Although the move will cost the retail chain $2B in annual sales, CVS is banking that the distinction can help it win business in other parts of the company.
CVS vs. ETF Alternatives
Other News & PR